{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T07:08:46Z","timestamp":1790233726586,"version":"4.1.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T00:00:00Z","timestamp":1739750400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T00:00:00Z","timestamp":1739750400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"FPU grant from The Spanish Ministry of Education and Professional training","award":["FPU21\/00042"],"award-info":[{"award-number":["FPU21\/00042"]}]},{"name":"ISCIII (Instituto de Salud Carlos III), cofinanced by FSE","award":["CP19\/00114"],"award-info":[{"award-number":["CP19\/00114"]}]},{"name":"Instituto de Salud Carlos III and co-financed by the European Union","award":["PI20\/00203 and PI22\/00147"],"award-info":[{"award-number":["PI20\/00203 and PI22\/00147"]}]},{"name":"Gobierno de Navarra Proyecto ARNMUNE","award":["0011\u20131411-2023"],"award-info":[{"award-number":["0011\u20131411-2023"]}]},{"name":"Leonardo Grant for Researchers and Cultural Creators","award":["2022"],"award-info":[{"award-number":["2022"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nanobiotechnol"],"DOI":"10.1186\/s12951-025-03196-2","type":"journal-article","created":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T22:31:11Z","timestamp":1739831471000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Intraperitoneal administration of mRNA encoding interleukin-12 for immunotherapy in peritoneal carcinomatosis"],"prefix":"10.1186","volume":"23","author":[{"given":"Leire","family":"Arrizabalaga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia Augusta","family":"Di Trani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myriam","family":"Fern\u00e1ndez-Sendin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1ngela","family":"Bella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan Salvador","family":"Russo-Cabrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celia","family":"Gomar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuria","family":"Ardaiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Belsue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Gonz\u00e1lez-Gomariz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Zalba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adri\u00e1n","family":"Gil-Korilis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria J.","family":"Garrido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Melero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Aranda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Berraondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,17]]},"reference":[{"issue":"2","key":"3196_CR1","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1002\/(sici)1097-0142(20000115)88:2<358::aid-cncr16>3.0.co;2-o","volume":"15","author":"B Sadeghi","year":"2000","unstructured":"Sadeghi B, Arvieux C, Glehen O, et al. Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer Jan. 2000;15(2):358\u201363. https:\/\/doi.org\/10.1002\/(sici)1097-0142(20000115)88:2%3C;358::aid-cncr16%3E;3.0.co;2-o","journal-title":"Cancer Jan"},{"issue":"41","key":"3196_CR2","doi-asserted-by":"publisher","first-page":"6979","DOI":"10.3748\/wjg.v19.i41.6979","volume":"7","author":"F Coccolini","year":"2013","unstructured":"Coccolini F, Gheza F, Lotti M, et al. Peritoneal carcinomatosis. World J Gastroenterol Nov. 2013;7(41):6979\u201394. https:\/\/doi.org\/10.3748\/wjg.v19.i41.6979","journal-title":"World J Gastroenterol Nov"},{"issue":"10","key":"3196_CR3","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1158\/1078-0432.CCR-22-0201","volume":"13","author":"F Aranda","year":"2022","unstructured":"Aranda F, Eguren-Santamaria I, Bella A, Berraondo P, Melero I. Revisiting Intracavitary Immunotherapy of Cancer. Clin Cancer Res May. 2022;13(10):1993\u20135. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-0201","journal-title":"Clin Cancer Res May"},{"issue":"20","key":"3196_CR4","doi-asserted-by":"publisher","first-page":"3737","DOI":"10.1200\/JCO.2003.04.187","volume":"15","author":"VJ Verwaal","year":"2003","unstructured":"Verwaal VJ, van Ruth S, de Bree E, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol Oct. 2003;15(20):3737\u201343. https:\/\/doi.org\/10.1200\/JCO.2003.04.187","journal-title":"J Clin Oncol Oct"},{"issue":"1","key":"3196_CR5","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41572-021-00326-6","volume":"16","author":"D Cortes-Guiral","year":"2021","unstructured":"Cortes-Guiral D, Hubner M, Alyami M, et al. Primary and metastatic peritoneal surface malignancies. Nat Rev Dis Primers Dec. 2021;16(1):91. https:\/\/doi.org\/10.1038\/s41572-021-00326-6","journal-title":"Nat Rev Dis Primers Dec"},{"issue":"5","key":"3196_CR6","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1093\/annonc\/mdl499","volume":"18","author":"AA Ayantunde","year":"2007","unstructured":"Ayantunde AA, Parsons SL. Pattern and prognostic factors in patients with malignant ascites: a retrospective study. Ann Oncol May. 2007;18(5):945\u20139. https:\/\/doi.org\/10.1093\/annonc\/mdl499","journal-title":"Ann Oncol May"},{"key":"3196_CR7","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/bs.ircmb.2022.04.017","volume":"371","author":"A Bella","year":"2022","unstructured":"Bella A, Arrizabalaga L, Di Trani CA, et al. Omentum: friend or foe in ovarian cancer immunotherapy? Int Rev Cell Mol Biol. 2022;371:117\u201331. https:\/\/doi.org\/10.1016\/bs.ircmb.2022.04.017","journal-title":"Int Rev Cell Mol Biol"},{"issue":"1","key":"3196_CR8","doi-asserted-by":"publisher","first-page":"10541","DOI":"10.1038\/s41598-017-10940-8","volume":"5","author":"OO Yeku","year":"2017","unstructured":"Yeku OO, Purdon TJ, Koneru M, Spriggs D, Brentjens RJ. Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment. Sci Rep Sep. 2017;5(1):10541. https:\/\/doi.org\/10.1038\/s41598-017-10940-8","journal-title":"Sci Rep Sep"},{"issue":"5","key":"3196_CR9","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1038\/cgt.2016.14","volume":"23","author":"SC Katz","year":"2016","unstructured":"Katz SC, Point GR, Cunetta M, et al. Regional CAR-T cell infusions for peritoneal carcinomatosis are superior to systemic delivery. Cancer Gene Ther May. 2016;23(5):142\u20138. https:\/\/doi.org\/10.1038\/cgt.2016.14","journal-title":"Cancer Gene Ther May"},{"issue":"1","key":"3196_CR10","doi-asserted-by":"publisher","first-page":"2147317","DOI":"10.1080\/2162402X.2022.2147317","volume":"12","author":"CA Di Trani","year":"2023","unstructured":"Di Trani CA, Cirella A, Arrizabalaga L, et al. Intracavitary adoptive transfer of IL-12 mRNA-engineered tumor-specific CD8(+) T cells eradicates peritoneal metastases in mouse models. Oncoimmunology. 2023;12(1):2147317. https:\/\/doi.org\/10.1080\/2162402X.2022.2147317","journal-title":"Oncoimmunology"},{"key":"3196_CR11","doi-asserted-by":"publisher","unstructured":"Gebremeskel S, Nelson A, Walker B, et al. Natural killer T cell immunotherapy combined with oncolytic vesicular stomatitis virus or reovirus treatments differentially increases survival in mouse models of ovarian and breast cancer metastasis. J Immunother Cancer Mar. 2021;9(3). https:\/\/doi.org\/10.1136\/jitc-2020-002096","DOI":"10.1136\/jitc-2020-002096"},{"issue":"3","key":"3196_CR12","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1158\/2326-6066.CIR-16-0162","volume":"5","author":"AA Alkayyal","year":"2017","unstructured":"Alkayyal AA, Tai LH, Kennedy MA, et al. NK-Cell recruitment is necessary for eradication of peritoneal carcinomatosis with an IL12-Expressing Maraba Virus Cellular Vaccine. Cancer Immunol Res Mar. 2017;5(3):211\u201321. https:\/\/doi.org\/10.1158\/2326-6066.CIR-16-0162","journal-title":"Cancer Immunol Res Mar"},{"issue":"1","key":"3196_CR13","doi-asserted-by":"publisher","first-page":"2098657","DOI":"10.1080\/2162402X.2022.2098657","volume":"11","author":"A Bella","year":"2022","unstructured":"Bella A, Arrizabalaga L, Di Trani CA, et al. Synergistic antitumor response with recombinant modified virus Ankara armed with CD40L and CD137L against peritoneal carcinomatosis. Oncoimmunology. 2022;11(1):2098657. https:\/\/doi.org\/10.1080\/2162402X.2022.2098657","journal-title":"Oncoimmunology"},{"issue":"1","key":"3196_CR14","doi-asserted-by":"publisher","first-page":"e1515058","DOI":"10.1080\/2162402X.2018.1515058","volume":"8","author":"A Perales-Puchalt","year":"2019","unstructured":"Perales-Puchalt A, Svoronos N, Villarreal DO, et al. IL-33 delays metastatic peritoneal cancer progression inducing an allergic microenvironment. Oncoimmunology. 2019;8(1):e1515058. https:\/\/doi.org\/10.1080\/2162402X.2018.1515058","journal-title":"Oncoimmunology"},{"key":"3196_CR15","doi-asserted-by":"publisher","unstructured":"Pauli G, Chao PH, Qin Z, Bottger R, Lee SE, Li SD. Liposomal Resiquimod for enhanced immunotherapy of peritoneal metastases of Colorectal Cancer. Pharm Oct. 2021;15(10). https:\/\/doi.org\/10.3390\/pharmaceutics13101696","DOI":"10.3390\/pharmaceutics13101696"},{"key":"3196_CR16","doi-asserted-by":"publisher","first-page":"663379","DOI":"10.3389\/fimmu.2021.663379","volume":"12","author":"OO Yeku","year":"2021","unstructured":"Yeku OO, Rao TD, Laster I, et al. Bispecific T-Cell engaging antibodies against MUC16 demonstrate efficacy against ovarian Cancer in Monotherapy and in combination with PD-1 and VEGF inhibition. Front Immunol. 2021;12:663379. https:\/\/doi.org\/10.3389\/fimmu.2021.663379","journal-title":"Front Immunol"},{"issue":"2","key":"3196_CR17","doi-asserted-by":"publisher","first-page":"129","DOI":"10.4161\/mabs.2.2.11221","volume":"2","author":"R Linke","year":"2010","unstructured":"Linke R, Klein A, Seimetz D. Catumaxomab: clinical development and future directions. MAbs Mar-Apr. 2010;2(2):129\u201336. https:\/\/doi.org\/10.4161\/mabs.2.2.11221","journal-title":"MAbs Mar-Apr"},{"issue":"10","key":"3196_CR18","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1038\/nrd.2018.132","volume":"17","author":"F Pastor","year":"2018","unstructured":"Pastor F, Berraondo P, Etxeberria I, et al. An RNA toolbox for cancer immunotherapy. Nat Rev Drug Discov Oct. 2018;17(10):751\u201367. https:\/\/doi.org\/10.1038\/nrd.2018.132","journal-title":"Nat Rev Drug Discov Oct"},{"issue":"10","key":"3196_CR19","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/nrd4278","volume":"13","author":"U Sahin","year":"2014","unstructured":"Sahin U, Kariko K, Tureci O. mRNA-based therapeutics\u2013developing a new class of drugs. Nat Rev Drug Discov Oct. 2014;13(10):759\u201380. https:\/\/doi.org\/10.1038\/nrd4278","journal-title":"Nat Rev Drug Discov Oct"},{"issue":"7549","key":"3196_CR20","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1038\/nature14426","volume":"30","author":"S Kreiter","year":"2015","unstructured":"Kreiter S, Vormehr M, van de Roemer N, et al. Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nat Apr. 2015;30(7549):692\u20136. https:\/\/doi.org\/10.1038\/nature14426","journal-title":"Nat Apr"},{"issue":"748","key":"3196_CR21","doi-asserted-by":"publisher","first-page":"eadl2720","DOI":"10.1126\/scitranslmed.adl2720","volume":"22","author":"CR Stadler","year":"2024","unstructured":"Stadler CR, Ellinghaus U, Fischer L, et al. Preclinical efficacy and pharmacokinetics of an RNA-encoded T cell-engaging bispecific antibody targeting human claudin 6. Sci Transl Med May. 2024;22(748):eadl2720. https:\/\/doi.org\/10.1126\/scitranslmed.adl2720","journal-title":"Sci Transl Med May"},{"issue":"4","key":"3196_CR22","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/j.ccell.2024.02.013","volume":"8","author":"JD Beck","year":"2024","unstructured":"Beck JD, Diken M, Suchan M, et al. Long-lasting mRNA-encoded interleukin-2 restores CD8(+) T cell neoantigen immunity in MHC class I-deficient cancers. Cancer Cell Apr. 2024;8(4):568\u2013e58211. https:\/\/doi.org\/10.1016\/j.ccell.2024.02.013","journal-title":"Cancer Cell Apr"},{"issue":"4","key":"3196_CR23","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.ccell.2024.02.015","volume":"8","author":"P Berraondo","year":"2024","unstructured":"Berraondo P, Gomis G, Melero I. The liver as a cytokine factory working on mRNA blueprints for cancer immunotherapy. Cancer Cell Apr. 2024;8(4):502\u20134. https:\/\/doi.org\/10.1016\/j.ccell.2024.02.015","journal-title":"Cancer Cell Apr"},{"key":"3196_CR24","doi-asserted-by":"publisher","unstructured":"Hewitt SL, Bai A, Bailey D, et al. Durable anticancer immunity from intratumoral administration of IL-23, IL-36gamma, and OX40L mRNAs. Sci Transl Med Jan. 2019;30(477). https:\/\/doi.org\/10.1126\/scitranslmed.aat9143","DOI":"10.1126\/scitranslmed.aat9143"},{"key":"3196_CR25","doi-asserted-by":"publisher","unstructured":"Hewitt SL, Bailey D, Zielinski J et al. Intratumoral IL12 mRNA Therapy Promotes TH1 Transformation of the Tumor Microenvironment. Clin Cancer Res. Dec 1. 2020;26(23):6284\u20136298. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-0472","DOI":"10.1158\/1078-0432.CCR-20-0472"},{"issue":"2","key":"3196_CR26","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1158\/2326-6066.CIR-22-0373","volume":"3","author":"A Cirella","year":"2023","unstructured":"Cirella A, Bolanos E, Di Trani CA, et al. Intratumoral Gene transfer of mRNAs encoding IL12 in combination with decoy-resistant IL18 improves local and systemic Antitumor immunity. Cancer Immunol Res Feb. 2023;3(2):184\u201398. https:\/\/doi.org\/10.1158\/2326-6066.CIR-22-0373","journal-title":"Cancer Immunol Res Feb"},{"issue":"610","key":"3196_CR27","doi-asserted-by":"publisher","first-page":"eabc7804","DOI":"10.1126\/scitranslmed.abc7804","volume":"8","author":"C Hotz","year":"2021","unstructured":"Hotz C, Wagenaar TR, Gieseke F, et al. Local delivery of mRNA-encoded cytokines promotes antitumor immunity and tumor eradication across multiple preclinical tumor models. Sci Transl Med Sep. 2021;8(610):eabc7804. https:\/\/doi.org\/10.1126\/scitranslmed.abc7804","journal-title":"Sci Transl Med Sep"},{"issue":"7","key":"3196_CR28","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1136\/gutjnl-2019-318269","volume":"68","author":"P Berraondo","year":"2019","unstructured":"Berraondo P, Martini PGV, Avila MA, Fontanellas A. Messenger RNA therapy for rare genetic metabolic diseases. Gut Jul. 2019;68(7):1323\u201330. https:\/\/doi.org\/10.1136\/gutjnl-2019-318269","journal-title":"Gut Jul"},{"issue":"12","key":"3196_CR29","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","volume":"6","author":"X Hou","year":"2021","unstructured":"Hou X, Zaks T, Langer R, Dong Y. Lipid nanoparticles for mRNA delivery. Nat Rev Mater. 2021;6(12):1078\u201394. https:\/\/doi.org\/10.1038\/s41578-021-00358-0","journal-title":"Nat Rev Mater"},{"issue":"24","key":"3196_CR30","doi-asserted-by":"publisher","first-page":"10025","DOI":"10.1021\/acs.nanolett.2c03741","volume":"28","author":"K Paunovska","year":"2022","unstructured":"Paunovska K, Da Silva Sanchez AJ, Lokugamage MP, et al. The extent to which lipid nanoparticles require apolipoprotein E and low-density lipoprotein receptor for delivery changes with ionizable lipid structure. Nano Lett Dec. 2022;28(24):10025\u201333. https:\/\/doi.org\/10.1021\/acs.nanolett.2c03741","journal-title":"Nano Lett Dec"},{"issue":"1","key":"3196_CR31","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41596-022-00755-x","volume":"18","author":"X Wang","year":"2023","unstructured":"Wang X, Liu S, Sun Y, et al. Preparation of selective organ-targeting (SORT) lipid nanoparticles (LNPs) using multiple technical methods for tissue-specific mRNA delivery. Nat Protoc Jan. 2023;18(1):265\u201391. https:\/\/doi.org\/10.1038\/s41596-022-00755-x","journal-title":"Nat Protoc Jan"},{"issue":"4","key":"3196_CR32","doi-asserted-by":"publisher","first-page":"eade1444","DOI":"10.1126\/sciadv.ade1444","volume":"27","author":"JR Melamed","year":"2023","unstructured":"Melamed JR, Yerneni SS, Arral ML, et al. Ionizable lipid nanoparticles deliver mRNA to pancreatic beta cells via macrophage-mediated gene transfer. Sci Adv Jan. 2023;27(4):eade1444. https:\/\/doi.org\/10.1126\/sciadv.ade1444","journal-title":"Sci Adv Jan"},{"key":"3196_CR33","doi-asserted-by":"publisher","unstructured":"Lewis CR, Dadgar N, Yellin SA, et al. Regional Immunotherapy for Peritoneal Carcinomatosis in Gastroesophageal Cancer: emerging strategies to Re-condition a maladaptive Tumor Environment. Cancers (Basel) Oct. 2023;23(20). https:\/\/doi.org\/10.3390\/cancers15205107","DOI":"10.3390\/cancers15205107"},{"issue":"2","key":"3196_CR34","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1046\/j.1365-3083.1996.d01-297.x","volume":"44","author":"U Kubicka","year":"1996","unstructured":"Kubicka U, Olszewski WL, Tarnowski W, Bielecki K, Ziolkowska A, Wierzbicki Z. Normal human immune peritoneal cells: subpopulations and functional characteristics. Scand J Immunol Aug. 1996;44(2):157\u201363. https:\/\/doi.org\/10.1046\/j.1365-3083.1996.d01-297.x","journal-title":"Scand J Immunol Aug"},{"issue":"1","key":"3196_CR35","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/s42003-020-01246-z","volume":"22","author":"V Krishnan","year":"2020","unstructured":"Krishnan V, Tallapragada S, Schaar B, et al. Omental macrophages secrete chemokine ligands that promote ovarian cancer colonization of the omentum via CCR1. Commun Biol Sep. 2020;22(1):524. https:\/\/doi.org\/10.1038\/s42003-020-01246-z","journal-title":"Commun Biol Sep"},{"key":"3196_CR36","doi-asserted-by":"publisher","first-page":"607945","DOI":"10.3389\/fimmu.2020.607945","volume":"11","author":"MV Baranov","year":"2020","unstructured":"Baranov MV, Kumar M, Sacanna S, Thutupalli S, van den Bogaart G. Modulation of Immune responses by particle size and shape. Front Immunol. 2020;11:607945. https:\/\/doi.org\/10.3389\/fimmu.2020.607945","journal-title":"Front Immunol"},{"key":"3196_CR37","doi-asserted-by":"publisher","first-page":"4521","DOI":"10.2147\/IJN.S421173","volume":"18","author":"A Wroblewska","year":"2023","unstructured":"Wroblewska A, Szczygiel A, Szermer-Olearnik B, Pajtasz-Piasecka E. Macrophages as Promising Carriers for Nanoparticle Delivery in Anticancer Therapy. Int J Nanomed. 2023;18:4521\u201339. https:\/\/doi.org\/10.2147\/IJN.S421173","journal-title":"Int J Nanomed"},{"issue":"16","key":"3196_CR38","first-page":"4696","volume":"15","author":"JG Segal","year":"2002","unstructured":"Segal JG, Lee NC, Tsung YL, Norton JA, Tsung K. The role of IFN-gamma in rejection of established tumors by IL-12: source of production and target. Cancer Res Aug. 2002;15(16):4696\u2013703.","journal-title":"Cancer Res Aug"},{"issue":"2","key":"3196_CR39","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1097\/00002371-199502000-00001","volume":"17","author":"MJ Brunda","year":"1995","unstructured":"Brunda MJ, Luistro L, Hendrzak JA, Fountoulakis M, Garotta G, Gately MK. Role of interferon-gamma in mediating the antitumor efficacy of interleukin-12. J Immunother Emphas Tumor Immunol Feb. 1995;17(2):71\u20137. https:\/\/doi.org\/10.1097\/00002371-199502000-00001","journal-title":"J Immunother Emphas Tumor Immunol Feb"},{"issue":"2","key":"3196_CR40","doi-asserted-by":"publisher","first-page":"169","DOI":"10.3748\/wjg.v6.i2.169","volume":"6","author":"C Platell","year":"2000","unstructured":"Platell C, Cooper D, Papadimitriou JM, Hall JC. The omentum. World J Gastroenterol Apr. 2000;6(2):169\u201376. https:\/\/doi.org\/10.3748\/wjg.v6.i2.169","journal-title":"World J Gastroenterol Apr"},{"issue":"5","key":"3196_CR41","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/j.immuni.2009.03.014","volume":"30","author":"J Rangel-Moreno","year":"2009","unstructured":"Rangel-Moreno J, Moyron-Quiroz JE, Carragher DM, et al. Omental milky spots develop in the absence of lymphoid tissue-inducer cells and support B and T cell responses to peritoneal antigens. Immun May. 2009;30(5):731\u201343. https:\/\/doi.org\/10.1016\/j.immuni.2009.03.014","journal-title":"Immun May"},{"issue":"7","key":"3196_CR42","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/j.it.2017.03.002","volume":"38","author":"S Meza-Perez","year":"2017","unstructured":"Meza-Perez S, Randall TD. Immunological functions of the Omentum. Trends Immunol Jul. 2017;38(7):526\u201336. https:\/\/doi.org\/10.1016\/j.it.2017.03.002","journal-title":"Trends Immunol Jul"},{"issue":"2","key":"3196_CR43","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.4049\/jimmunol.0900409","volume":"15","author":"DA Carlow","year":"2009","unstructured":"Carlow DA, Gold MR, Ziltener HJ. Lymphocytes in the peritoneum home to the omentum and are activated by resident dendritic cells. J Immunol Jul. 2009;15(2):1155\u201365. https:\/\/doi.org\/10.4049\/jimmunol.0900409","journal-title":"J Immunol Jul"},{"key":"3196_CR44","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.jconrel.2015.08.007","volume":"10","author":"N Pardi","year":"2015","unstructured":"Pardi N, Tuyishime S, Muramatsu H, et al. Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes. J Control Release Nov. 2015;10:217:345\u201351. https:\/\/doi.org\/10.1016\/j.jconrel.2015.08.007","journal-title":"J Control Release Nov"},{"issue":"9","key":"3196_CR45","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1007\/s11095-019-2646-z","volume":"24","author":"M Shariati","year":"2019","unstructured":"Shariati M, Zhang H, Van de Sande L, et al. High pressure nebulization (PIPAC) Versus Injection for the Intraperitoneal Administration of mRNA complexes. Pharm Res Jun. 2019;24(9):126. https:\/\/doi.org\/10.1007\/s11095-019-2646-z","journal-title":"Pharm Res Jun"},{"issue":"1","key":"3196_CR46","doi-asserted-by":"publisher","first-page":"4701","DOI":"10.1038\/s41467-024-49034-1","volume":"3","author":"Z Zou","year":"2024","unstructured":"Zou Z, Shen J, Xue D, et al. Anti-PD-1 cis-delivery of low-affinity IL-12 activates intratumoral CD8(+)T cells for systemic antitumor responses. Nat Commun Jun. 2024;3(1):4701. https:\/\/doi.org\/10.1038\/s41467-024-49034-1","journal-title":"Nat Commun Jun"},{"key":"3196_CR47","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.omtn.2023.07.020","volume":"12","author":"CA Di Trani","year":"2023","unstructured":"Di Trani CA, Cirella A, Arrizabalaga L, et al. Intratumoral injection of IL-12-encoding mRNA targeted to CSFR1 and PD-L1 exerts potent anti-tumor effects without substantial systemic exposure. Mol Ther Nucleic Acids. Sep 2023;12:33:599\u2013616. https:\/\/doi.org\/10.1016\/j.omtn.2023.07.020","journal-title":"Mol Ther Nucleic Acids"},{"key":"3196_CR48","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1016\/j.omtn.2023.07.026","volume":"12","author":"A Cirella","year":"2023","unstructured":"Cirella A, Bolanos E, Luri-Rey C, et al. Intratumoral immunotherapy with mRNAs encoding chimeric protein constructs encompassing IL-12, CD137 agonists, and TGF-beta antagonists. Mol Ther Nucleic Acids. Sep 2023;12:33:668\u201382. https:\/\/doi.org\/10.1016\/j.omtn.2023.07.026","journal-title":"Mol Ther Nucleic Acids"},{"issue":"4","key":"3196_CR49","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1038\/s41565-023-01580-3","volume":"19","author":"M Liu","year":"2024","unstructured":"Liu M, Hu S, Yan N, Popowski KD, Cheng K. Inhalable extracellular vesicle delivery of IL-12 mRNA to treat lung cancer and promote systemic immunity. Nat Nanotechnol Apr. 2024;19(4):565\u201375. https:\/\/doi.org\/10.1038\/s41565-023-01580-3","journal-title":"Nat Nanotechnol Apr"},{"key":"3196_CR50","doi-asserted-by":"publisher","first-page":"575597","DOI":"10.3389\/fimmu.2020.575597","volume":"11","author":"KG Nguyen","year":"2020","unstructured":"Nguyen KG, Vrabel MR, Mantooth SM, et al. Localized Interleukin-12 for Cancer Immunotherapy. Front Immunol. 2020;11:575597. https:\/\/doi.org\/10.3389\/fimmu.2020.575597","journal-title":"Front Immunol"},{"key":"3196_CR51","doi-asserted-by":"publisher","unstructured":"Bella A, Arrizabalaga L, Di Trani CA, et al. Intraperitoneal administration of a modified vaccinia virus Ankara confers single-chain interleukin-12 expression to the omentum and achieves immune-mediated efficacy against peritoneal carcinomatosis. J Immunother Cancer Nov. 2023;11(11). https:\/\/doi.org\/10.1136\/jitc-2023-006702","DOI":"10.1136\/jitc-2023-006702"},{"issue":"3","key":"3196_CR52","doi-asserted-by":"publisher","first-page":"e994446","DOI":"10.4161\/2162402X.2014.994446","volume":"4","author":"M Koneru","year":"2015","unstructured":"Koneru M, Purdon TJ, Spriggs D, Koneru S, Brentjens RJ. IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo. Oncoimmunology Mar. 2015;4(3):e994446. https:\/\/doi.org\/10.4161\/2162402X.2014.994446","journal-title":"Oncoimmunology Mar"},{"issue":"6","key":"3196_CR53","doi-asserted-by":"publisher","first-page":"2663","DOI":"10.1128\/JVI.02384-08","volume":"83","author":"J Crettaz","year":"2009","unstructured":"Crettaz J, Otano I, Ochoa-Callejero L, et al. Treatment of chronic viral hepatitis in woodchucks by prolonged intrahepatic expression of interleukin-12. J Virol Mar. 2009;83(6):2663\u201374. https:\/\/doi.org\/10.1128\/JVI.02384-08","journal-title":"J Virol Mar"},{"issue":"6","key":"3196_CR54","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/j.jhep.2007.07.025","volume":"47","author":"M Zabala","year":"2007","unstructured":"Zabala M, Lasarte JJ, Perret C, et al. Induction of immunosuppressive molecules and regulatory T cells counteracts the antitumor effect of interleukin-12-based gene therapy in a transgenic mouse model of liver cancer. J Hepatol Dec. 2007;47(6):807\u201315. https:\/\/doi.org\/10.1016\/j.jhep.2007.07.025","journal-title":"J Hepatol Dec"}],"container-title":["Journal of Nanobiotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-025-03196-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12951-025-03196-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-025-03196-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T22:31:26Z","timestamp":1739831486000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnanobiotechnology.biomedcentral.com\/articles\/10.1186\/s12951-025-03196-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,17]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3196"],"URL":"https:\/\/doi.org\/10.1186\/s12951-025-03196-2","relation":{},"ISSN":["1477-3155"],"issn-type":[{"value":"1477-3155","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,17]]},"assertion":[{"value":"29 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All the experiments received approval (R-080\u201319GN) from the Ethics Committee for Animal Testing at the University of Navarra.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Ignacio Melero reports receiving commercial research grants from AstraZeneca, BMS, Highlight Therapeutics, Alligator, Pfizer Genmab and Roche; has received speakers bureau honoraria from MSD; and is a consultant or advisory board member for BMS, Roche, AstraZeneca, Genmab, Pharmamar, F-Star, Bioncotech, Bayer, Numab, Pieris, Gossamer, Alligator and Merck Seron.The rest of the authors report no conflicts of interest in this work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"113"}}